logo-loader
RNS
Haleon PLC

Haleon PLC - Transactions in Own Shares

RNS Number : 2770H
Haleon PLC
08 June 2026
 

Icon Description automatically generated

 

Haleon plc: Aggregated information - transactions in own shares

 

8 June 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 16,585,448 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.

 


London Stock Exchange

CBOE (UK)/BXE

CBOE (UK)/CXE

Aquis

Date of purchase:

1 June 2026

Number of Shares purchased:

3,673,823

2,784,141

884,017

438,324

Highest price paid per Share (p):

334.1000

333.9000

334.1000

333.6000

Lowest price paid per Share (p):

327.1000

326.9000

329.3000

330.5000

Volume weighted average price paid per Share (p):

329.6854

329.5691

331.8523

332.1204

Date of purchase:

2 June 2026

Number of Shares purchased:

3,592,476

1,992,902

893,149

445,097

Highest price paid per Share (p):

327.5000

327.1000

327.5000

326.6000

Lowest price paid per Share (p):

319.9000

319.9000

320.4000

321.2000

Volume weighted average price paid per Share (p):

322.0103

321.7628

323.3163

323.6575

Date of purchase:

3 June 2026

Number of Shares purchased:

1,750,781

45,821

48,613

35,602

Highest price paid per Share (p):

323.0000

323.0000

323.0000

323.0000

Lowest price paid per Share (p):

317.9000

319.2000

319.2000

319.2000

Volume weighted average price paid per Share (p):

320.4053

320.8002

321.0249

320.8212

Date of purchase:

4 June 2026

Number of Shares purchased:

113

189

179

221

Highest price paid per Share (p):

324.0000

324.0000

324.0000

324.0000

Lowest price paid per Share (p):

324.0000

324.0000

324.0000

324.0000

Volume weighted average price paid per Share (p):

324.0000

324.0000

324.0000

324.0000

Date of purchase:

5 June 2026

Number of Shares purchased:

-

-

-

-

Highest price paid per Share (p):

-

-

-

-

Lowest price paid per Share (p):

-

-

-

-

Volume weighted average price paid per Share (p):

-

-

-

-

 

Following the settlement of the above, the Company's registered share capital is 8,842,752,346 ordinary shares of £0.01 each, of which 12,063,502 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,830,688,844 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/2770H_1-2026-6-5.pdf

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

 

Enquiries

 

 

Investors

Media

 

Jo Russell  

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel     

+44 7552 484646

Victoria Durman

+44 7894 505730

Email: investor-relations@haleon.com

Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSBLGDLRXGDGLU
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read